In 2009, a novel triple reassortant influenza H1N1 virus of swine origin emerged in Mexico and quickly spread worldwide, resulting in the first pandemic in 40 years. Although the majority of the US population was expected to have little to low preexisting immunity to this novel H1N1 virus [1] , the overall mortality associated with the 2009 influenza H1N1 pandemic was significantly less than that associated with the 1968 H3N2 ''Hong Kong flu'' and was comparable to that resulting from seasonal influenza [2] . The cumulative excess deaths caused by pandemic H1N1 were fewer than expected among older adults, especially among those aged $65 years [2] . These observations suggest that older adults (age, $50 years) might have some crossprotective immunity from earlier exposure to related influenza viruses.
Phylogenetic analysis shows that the pandemic H1N1 hemagglutinin (HA) gene is most closely related to that of A/New Jersey/76-like virus [3] , another human virus of swine origin isolated during a regional outbreak of ''swine flu'' at Fort Dix military base, New Jersey. The fear that this outbreak might lead to a pandemic triggered a nationwide vaccination campaign, resulting in approximately 45 million US persons being vaccinated against A/New Jersey/76-like virus [4] . However, the impact of this vaccination campaign 30 years ago on pandemic H1N1 is unclear. We recently retrieved .200 pairs of human serum samples collected during the 1976 swine flu vaccine trials from the archives of the Center for Biologics Evaluation and Research (CBER, formerly the Bureau of Biologics) at the US Food and Drug Administration (FDA). CBER/FDA, along with the National Institutes of Health and the Centers for Disease Control and Prevention, had led the 1976 swine flu vaccine investigations. Using these archived serum samples, we determined the cross-reactivity of HA inhibition (HAI) and neuraminidase (NA) inhibition (NAI) antibodies induced by the 1976 swine flu vaccines toward pandemic H1N1 viruses and evaluated their protective potential in naive mice against pandemic H1N1 infection.
METHODS

Ethics Statement
All the human serum samples used in the present study were analyzed anonymously at CBER/FDA.
Viruses
The following wild-type (wt) viruses were used in the study: Medical College) was mixed with the pHW2000 plasmids expressing the NA gene of NJ/76 (N1 NJ ) or California/04 (N1 CA ) and the 6 internal genes of A/Puerto Rico/8/34 (H1N1, PR8) to generate H6N1 NJ or H6N1 CA reassortants by reverse genetics [5, 6] . The H5 VN N1 CA reassortant was generated also using the pHW2000 vectors expressing the H5 VN HA gene (multibasic cleavage site deleted) of A/Vietnam/1203/2004 (H5N1, Vietnam/1203), the N1 CA NA gene of California/04, and the 6 internal genes of PR8. Unless specified otherwise, all wt viruses and reassortants were amplified in 9-day-old embryonated eggs, and aliquots were stored at 270°C until use.
Vaccinated Human Serum Samples
Human serum panels (pre-and postvaccination) were collected during the 1976 swine flu vaccine trials. These clinical trials involved healthy volunteers aged 18-24 years at the time of the study. The corresponding clinical protocols were preapproved by the National Institutes of Health, Bureau of Biologics/FDA, and George Washington University clinical research review boards, with written informed consent provided at enrollment. Unless otherwise indicated, 101 pairs of human serum samples were retrieved from clinical trials that administered a single dose of A/New Jersey/76 monovalent vaccine (A/Monovalent) to participants intramuscularly at 200 chick cell-agglutinating (CCA) units/dose. Another 120 pairs of human serum samples were from clinical trials that gave participants an injection (intramuscularly) of a bivalent A vaccine (A/Bivalent) in the left arm and a monovalent B vaccine (B/Monovalent) in the right arm. The A/Bivalent vaccine contained 400 CCA units each of A/New Jersey/76 (H1N1) and A/Victoria/75 (H3N2)-like viruses per dose, and the B/Monovalent vaccine contained approximately 500 CCA units/dose of B/Hong Kong/72-like virus. Details of these clinical trials have been reported elsewhere [7] [8] [9] .
Hemagglutinin Inhibition Assay
Serum samples were pretreated with receptor-destroying enzyme (Denka-Seiken) before the HAI assay at a starting dilution of 1:10 with use of 4 HA units of virus and 0.5% turkey erythrocytes according to procedures described elsewhere [10, 11] . HAI titers were expressed as the reciprocal of the highest serum dilution that resulted in complete inhibition of hemagglutination. A titer of 5 was assigned if no inhibition was observed at a serum dilution of 1:10.
Neuraminidase Inhibition Assay
A subset of archived human serum samples were randomly selected from the 1976 A/Monovalent trials (45 pairs) and the A/Bivalent 1 B/Monovalent combination trials (38 pairs). NAI titers were determined using an enzyme-linked lectin assay [12, 13] . In brief, 2-fold serial dilutions of human serum samples were mixed with an equal volume of a predetermined amount of H6N1 NJ or H6N1 CA virions in fetuin-coated microtiter plates. The plates were incubated at 37°C for 16-18 hours After washing, peroxidase-labeled peanut agglutinin was added, followed by addition of o-phenylenediamine dihydrochloride 2 hours later. The color development was stopped by addition of 1 N H 2 SO 4 and was read at 490 nm on a Victor V multilabel plate reader (PerkinElmer). NAI titers were expressed as the reciprocal of the highest serum dilution that resulted in $50% inhibition of NA activity. A titer of 5 was assigned if ,50% inhibition of NA activity was measured at a 1:10 dilution.
Passive Transfer of Human Serum Samples
Ten pairs of human serum samples were selected from the 1976 swine flu vaccine trials for a passive transfer study using the following criteria: (1) showing at least a 4-fold increase in the titers of both HAI and NAI antibodies cross-reacting with HA and NA of California/04 after vaccination and (2) showing no cross-reactivity toward H5 VN HA of Vietnam/1203 by HAI assay.
Eight-week-old specific-pathogen-free female BALB/c mice (Taconic Farms) were housed in a biosafety level 2 facility at CBER/FDA under protocols approved by the Animal Care and Use Committee of CBER/FDA. Naive mice were ear punched and were intravenously injected with 100 lL of individual human sera. Six hours later, recipient mice were challenged intranasally with two 50% mouse lethal doses (MLD 50 ) of Madin-Darby canine kidney-amplified wt California/04 or egggrown H5 VN N1 CA reassortant. Separate sets of naive mice receiving 100 lL per mouse (intravenously) of pooled California/ 04-specific mouse hyperimmune serum samples or Vietnam/ 1203-specific mouse hyperimmune serum samples were included as positive controls. Naive mice receiving 100 lL per mouse (intravenously) of sterile phosphate-buffered saline served as negative controls. Body weight and mortality were monitored daily for 14 days after challenge.
Data Analysis and Statistics
HAI and NAI titers were analyzed for the following: geometric means of titers for HAI or NAI, seroprotection rates (the proportions of persons with HAI titers $40), seroconversion rates (the proportions of persons with a $4-fold increase in HAI titers), and the proportions of persons with a $4-fold increase in NAI titers. A correlation analysis between virus-specific HAI titers and NAI titers was performed using nonparametric Spearman q test (JMP statistical software, version 7). The correlation between virus-specific HAI or NAI titers of selected human serum samples and mouse survival/mortality status after challenge was analyzed using logistic fit with v 2 . A P value of ,.05 was considered statistically significant.
RESULTS
Cross-reactive Hemagglutinin Inhibition Antibodies Induced by the 1976 Swine Flu Vaccines
Administration of A/Monovalent or the combination of A/Bivalent and B/Monovalent resulted in similar NJ/76-specific HAI geometric mean titers (Table 1) , although participants given A/Monovalent had slightly higher seroprotection rate (23%) and seroconversion rate (23%) ( Figure 1A ). In general, the combined vaccination was not effective at inducing H3 and B strain-specific HAI antibodies, with only 3% seroprotection and seroconversion rates against Victoria/75 and HK/72, respectively (Table 1) .
Immunization with A/Monovalent vaccine alone or in combination with H3 and B strains yielded no cross-reactive HAI antibodies against a recent seasonal H1 vaccine strain, Brisbane/59 ( Figure 1B Abbreviations: CI, confidence interval; GMT: geometric mean titer; HAI, hemagglutinin inhibition. a The seroprotection rate is the proportion of subjects with HAI titers $40.
b The seroconversion rate is the proportion of subjects with a $4-fold rise in HAI titers.
46% and 44%, respectively, for A/Monovalent vaccination and 26% and 23%, respectively, for the combined vaccination ( Figure 1E ).
Cross-reactive Neuraminidase Inhibition Antibodies Induced by the 1976 Swine Flu Vaccines
Administration of A/Monovalent vaccine alone or in combination with H3 and B strains significantly elevated NJ/76-specific NAI antibodies from prevaccination levels (P 5 .001 for A/Monovalent; P , .05 for the combination; Figure 2A ). Sixty percent of the A/Monovalent vaccinees and 32% of the combined vaccine recipients had a $4-fold increase in NJ/76-specific NAI titers after vaccination. The A/Monovalent recipients had significantly elevated California/04-specific cross-reactive NAI titers, with 44% of them showing a $4-fold increase after vaccination (P , .001 for A/Monovalent; Figure 2B and data not shown). In contrast, the combined vaccination did not significantly increase cross-reactive NAI titers specific for California/04 despite 33% of the vaccinees having a $4-fold increase after vaccination ( Figure 2B and data not shown). Regardless of vaccinations, NJ/76-specific or California/04-specific NAI titers strongly correlated with their corresponding HAI titers in all enrolled participants (P , .001; data not shown).
Passive Transfer of Cross-reactive Hemagglutinin Inhibition and Neuraminidase Inhibition Antibodies Table 2 shows the survival/mortality status of mice that had received 100 lL per mouse (intravenously) of selected 1976 human serum samples, followed by a lethal challenge with wt California/04. Of 9 recipient mice that survived the lethal infection of wt California/04, 7 had received individual human serum samples with California/04-specific HAI titers $40 and California/04-specific NAI titers $160 (Table 2) . When the survival/mortality status of all 20 recipient mice in Table 1 was plotted against the original California/04-specific HAI or NAI titers of each corresponding human serum sample, only Naive female Balb/c mice were passively transferred intravenously with 100 lL per mouse of human serum samples selected from the 1976 swine flu vaccine trials. Six hours later, the mice were challenged intranasally with two 50% mouse lethal doses of wt California/04 (H1N1). Balb/c mice receiving 100 lL per mouse of California/04-specific mouse hyperimmune sera or 100 lL per mouse of PBS served as positive and negative controls, respectively. Survival was monitored for up to 14 days.
California/04-specific HAI titers, but not NAI titers, correlated significantly with survival/mortality of these mice ( Figure 3A and 3B). The correlation plot in Figure 3A indicated that transfer of serum samples with a higher California/04-specific HAI titer resulted in a greater possibility of survival from a lethal California/04 challenge. According to this correlation model, transfer of human serum samples with an estimated California/ 04-specific HAI titer of 43 (1 2 a 5 .95) predicted 50% survival/ death of recipient mice under the experimental conditions described ( Figure 3A) . To determine whether NA-specific antibodies could contribute to cross-protection, we evaluated the ability of the archived serum samples to protect naive mice against H5 VN N1 CA reassortant with a mismatched HA. The 10 pairs of selected 1976 human serum samples had no cross-reactive HAI antibodies against H5 VN HA (HAI titer of 5; Table 3 ). Six of 7 recipient mice that survived the lethal H5 VN N1 CA infection had received human serum samples with original California/04-specific NAI titers $320 (Table 3) . The survival/mortality status of the H5 VN N1 CA -challenged mice had no correlation with Vietnam/1203-specific HAI titers ( Figure 3C ), whereas a significant correlation was observed with the original California/04-specific NAI titers of the human serum samples transferred ( Figure 3D ). Transfer of human serum samples with an estimated NAI titer of 472 (1 2 a 5 .95) predicted 50% survival/death of recipient mice from a lethal infection of H5 VN N1 CA with a heterologous HA ( Figure 3D ). The correlation between virus-specific HAI or NAI titers of selected human sera and survival/mortality status of recipient mice was analyzed using logistic fit with v 2 . Blue * indicates survival (S) and red d represents mortality (M) after challenges. A, Correlation between California/04-specific HAI titer and survival/mortality of recipient mice after challenge with wt California/04; B, Correlation between California/04-specific NAI titer and survival/mortality of recipient mice after challenge with wt California/04; C, Correlation between Vietnam/1203-specific HAI titer and survival/ mortality of recipient mice after challenge with H5 VN N1 CA reassortant; D, Correlation between California/04-specific NAI titer and survival/mortality of recipient mice after challenge with H5 VN N1 CA reassortant. The numbers indicate the estimated HAI or NAI titers predictive of 50% survival by inverse prediction with 1 -a value at .95.
DISCUSSION
The global control of pandemic H1N1 was likely attributed to multilevel interventions implemented by individual countries, including heightened public awareness, application of personal protective masks and sanitary practices, school closures and social segregation, enhanced border surveillance, and wide distribution of effective pandemic vaccines and antivirals [14] . In addition to these, the 1976 swine flu epidemic might have also contributed to the reduced severity of pandemic H1N1 in the United States, because nearly one-quarter of the population was immunized against NJ/76-like virus [4] . Using archived serum samples from the 1976 swine flu vaccine trials, we examined the effect of the 1976 swine flu vaccines on cross-reactive HAI and NAI antibodies and their contributions to protection against pandemic H1N1 infection in mice.
As shown in this study, the 1976 inactivated vaccines, regardless of formulation, were not very immunogenic, with ,30% seroprotection and seroconversion rates for specific vaccine strains achieved. This is consistent with previous reports that a single dose of NJ/76 vaccination stimulated a poor HAI response in participants aged ,25 years [9, 15, 16] . Administration of NJ/76 monovalent vaccine alone or the combination of A/Bivalent and B/Monovalent resulted in similar levels of NJ/76-specific HAI response in all participants, suggesting that inclusion of H3N2 and B strains had no effect on the immunogenicity of 1976 swine flu vaccines. Recent clinical studies have also shown similar immunogenicity of pandemic A/California/07/2009 (California/07)-containing monovalent and trivalent vaccines in European adult and older volunteers [17] .
In the present study, we showed that immunization with NJ/ 76-like virus resulted in a cross-reactive HAI antibody response to California/07-like virus (California/04 and California/07 differ only in HA with a D223G change), but not to seasonal Brisbane/59 strain. This is consistent with the only other report on archived serum samples from persons immunized with NJ/76 monovalent vaccines [18] . However, no details regarding participants, vaccines, and immunization were revealed in that report. Meanwhile, McCullers et al [3] reported that recipients of the 1976 swine flu vaccines had high cross-reactive but nonneutralizing antibodies against pandemic H1N1 virus 30 years later. However, all persons enrolled in that study were health professionals who had been frequently exposed to influenza viruses or repeated seasonal vaccinations and were therefore not representative of the general population that received the 1976 swine flu vaccines. In addition, our results show that this pandemic H1N1-specific HAI cross-reactivity is not limited to the California/07-like vaccine strain, but also extends to its recent variants, including Ontario/RV3226 and SC/18. Surprisingly, immunization with A/Monovalent vaccine resulted in a 46% HAI seroprotection rate and 44% seroconversion rate against SC/18, almost twice the rates specific for the vaccine strain NJ/76. SC/18 is considered a low reactor with ferret hyperimmune serum specific for California/07 and is more distant than Ontario/RV3226 to California/07 in the evolutionary relationships of HA genes. The observed cross-reactivity of archived serum samples may also provide an explanation for our previous finding that 10%-15% of participants ($50 years) enrolled in the US 2009-2010 seasonal clinical trial had a baseline HAI titer of $40 against SC/18 [19] .
In addition to cross-reactive HAI response, we also examined the presence of cross-reactive NAI antibodies in these archived serum samples. It is well documented that NAI antibodies can be induced by natural infections or immunization and play a role in protection against influenza infection [20] [21] [22] [23] [24] [25] [26] . The 1976 swine flu vaccines contained NA at various levels [24] , and the NA genes of NJ/76 and California/04-like viruses are 82% identical in their amino acid sequences. Thus, it is not surprising that immunization against NJ/76 resulted in enhanced NAI responses that cross-reacted with pandemic H1N1 virus. The augmentation of virus-specific NAI response after A/Monovalent vaccination was higher than that after administration of the combined vaccines, implying that NA from additional strains might not synergistically enhance the immunogenicity of NA.
NA-specific antibodies can block the release of newly synthesized viral particles, reduce plaque sizes, and decrease virus yields in vitro but are unable to prevent infection in vivo [20, 27] . Previous studies have shown that NAI antibodies could inhibit pulmonary virus replication, reduce lung lesions in infected mice in the absence of a matched HAI response, and ease illness in human volunteers challenged with viruses bearing antigenically identical NA genes [21, 23, 28] . Murine hyperimmune serum samples derived from DNA vaccination against seasonal N1 NA provided some protection in recipient mice against H5N1 challenge [25] , suggesting that cross-reactive NAI antibodies might potentially enhance a host's resistance to heterologous influenza strains even without cross-reactive HAI responses. Marcelin et al [26] reported that seasonal vaccination enhanced pandemic H1N1-specific cross-reactive NAI antibodies in US adults and older persons, predominantly in those aged $60 years, which might have potentially contributed to the reduced severity of the 2009 pandemic in older adults.
In the current study, we directly addressed the role of crossreactive human HAI and NAI antibodies elicited by the 1976 swine flu vaccines in protection against pandemic H1N1 infection in mice. Our data clearly indicate that protection against wt California/04 was HAI dependent. We also directly demonstrate that human HAI antibodies elicited by the 1976 swine flu vaccination cross-protects against pandemic H1N1 virus in a mammalian species. In our model, transfer of human serum samples with an estimated HAI titer of 43 was predicted to provide 50% protection in recipient mice. An HAI titer of 40 is an established seroprotective measure that is considered to be associated with at least 50% reduction in the risk of influenza infection or disease in humans [29, 30] . The consistency between our estimate and the well-accepted seroprotective measure validates our model. Although there was no correlation of NAI titers with protection against wt California/04 in the presence of a cross-reactive HAI response, the NAI titers strongly correlated with survival of recipient mice challenged with a virus containing California/04 NA gene but a mismatched HA gene. In addition, we found that these selected 1976 human serum samples contained NAI antibodies cross-reacting with N3 NA and protected recipient mice from the lethality of an H5 VN N3 reassortant (data not shown). The 9 NA subtypes of influenza A fall into 2 distinct groups in the phylogenetic tree, with N1 in group 1 and N2 and N3 in group 2 separately [31] . The aforementioned crossreactivity is not surprising, because the 1976 swine flu vaccine recipients had been exposed to either an H3N2 virus or an H3N2-containing vaccine. Currently, there is no regulation of NA content in US licensed seasonal influenza vaccines. Our present study shows a potential benefit of cross-reactive NAI antibodies when a matched HAI response is deficient, thus urging further investigations in this topic and consideration of NA standardization in new influenza vaccines.
Taken together, our study demonstrates that the 1976 swine flu vaccination induced cross-reactive HAI and NAI antibodies that were functionally protective in mice, which might have had a positive effect on older adults in the United States during the influenza H1N1 pandemic.
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